VVY.AS Vivoryon Therapeutics NV

Healthcare Biotechnology Euronext Amsterdam
0.8240 EUR
Close of Oct 29, 2026
0.8240 1.65
Market cap
EUR 24.4M
P/E
-
P/B
15.71x
ROE
-865.9%
Dividend yield
-
Fundamental score
1.1/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is VVY.AS undervalued?

Graham number

The Graham number of Vivoryon Therapeutics NV cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Vivoryon Therapeutics NV fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-865.9%), below 10%.

ROA 0/1

Return on assets (-325.2%) is below the industry median (-19.8%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (58.5%) is above the industry median (3.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (4.9%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.2 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (15.7x) is above the industry median (3.1x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Vivoryon Therapeutics NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Vivoryon Therapeutics NV

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company i…

Full company profile